speaker
Conference Call Operator
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Charles River Laboratories third quarter 2026 earnings conference call. This conference call is being recorded at this time while participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this period, you will need to press star 1 on your telephone keypad. If you would like to remove yourself from the queue, please press star 2. Lastly, if you should need any operator assistance today, please press star 0. I would now like to turn the conference over to our host, Mr. Todd Spencer, Vice President, Investor Relations. Please go ahead, sir.

speaker
Todd Spencer
Vice President, Investor Relations

Good morning, and welcome to Charles River Laboratories' third quarter 2026 earnings conference call and webcast. This morning, I am pleased to be joined by Birgit Girshick, our Chief Executive Officer, and by Glenn Coleman, our Executive Vice President and Chief Financial Officer. They will comment on our results for the third quarter of 2026, as well as our financial guidance. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks which will be posted on the investor relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning approximately two hours after the call today and can also be accessed on the investor relations website. The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor. All remarks that we make about future expectations, plans and prospects for the company constitute forward-looking statements under federal securities law, including the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated. During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. Thank you, Todd, and good morning. We are pleased today to report another solid quarter with revenue and non-GAAP earnings per share

speaker
Birgit Girshick
Chief Executive Officer

that exceeded our prior outlook, continued momentum in the improving biopharmaceutical demand environment, and additional progress towards the execution of our pathway to purpose strategic vision. It was wonderful to see many of you at our investor day just over one month ago, and I hope that you found it to be an informative discussion about our strategic initiatives designed to enhance our operational excellence and strengthen our scientific leadership as well as our future growth drivers and long-term financial targets. As I mentioned, our focus is to simplify the company and move faster, invest where we can win and continue to lead as a scientific partner of choice for the critical work that our clients do. By executing on these goals, we believe it will translate into higher growth and operating margins, and Drivers Long-Term Shareholder Value Creation. We have made meaningful progress in recent months on initiatives to support our pathway-to-purpose strategy, which includes working to modernize our company and industry, strengthening our world-class scientific portfolio, and offering a customized, client-centric approach to drive growth. I will now provide you with highlights that demonstrate some of this progress, as well as our third quarter performance. We were encouraged by the acceleration of our revenue growth rate in the third quarter as we had anticipated, including solid, mid-single-digit organic growth in the DSA segment and high single-digit organic growth in the manufacturing segment. The solid DSA performance was supported by a net book to bell of 1.09 times in the third quarter, which marks the fourth consecutive quarter that the net book to bell has been above one times, averaging approximately 1.1 times over this period. Both the third quarter and trailing 12 months DSA booking performance were consistent with the levels needed to support our long-term financial targets With the CDMO business having been divested for a full quarter, we were also pleased to clearly see the underlying growth and margin trends emerged for the manufacturing segment and believe the outlook remains favorable for our comprehensive manufacturing quality control testing solution. We expect these collective trends to support the improvement to mid-single-digit organic growth for the company in the second half of this year, as well as the projected margin improvement. To enhance our ability to take advantage of improving the main trends, we are also working on our modernization efforts to drive greater efficiency, including through our Create the Future transformation programs. As an example, in July, we implemented a fully automated manufacturing suite for our Endosave endotoxin cartridge technology to increase cartridge production capacity, strengthen manufacturing controls, and enhance digital traceability. This upgrade improves quality and labor productivity and also increases cartridge production capacity by 14%. Also in our manufacturing segment, we partnered with Autolimus to launch Apollo Artisrate to digitize laboratory workflows and enhance client connectivity. This is a new capability for our Apollo platform, which will transform laboratory execution systems, increase efficiency, and provide greater transparency and collaboration for clients. These are two examples of progress in our Create the Future transformation program, which is expected to generate over $300 million in cumulative savings over the next four years and will be a key component to drive meaningful operating margin improvement in 2027 and beyond. We have also taken steps to continue to strengthen our scientific capabilities. We announced a collaboration with the FDA to validate preclinical screening tools to quantify and rank the abuse potential of new drugs. This collaboration is aimed at approving public health by helping to ensure the safety of drugs. As part of our efforts to further advance our Alternative Methods Advancement Project Initiative, or AMAP, We also introduced a new rapid cell banking program designed to significantly accelerate product release timelines in the biologics testing business. By combining rapid cell bank and release packages with advanced characterization using in vitro next generation sequencing capabilities, we will be able to reduce cell bank production timelines by 40% versus the industry standard of 20 weeks enabling clients who develop advanced therapies to reach key milestones and bring their innovative treatments to patients faster. In addition, we continue to pioneer in the space of virtual control groups, or VCGs, to selectively reduce animal use where scientifically appropriate. Last week, we announced that our VCG database and methodologies will now be used in a GOP-compliant safety assessment study for Ipsen, a biopharmaceutical client. This moves the use of VCGs from concept to regulatory submission. The execution of these kinds of initiatives is already benefiting us with clients. Because of our client-centric approach, and the value that we provide to our clients through the global breadth and scientific depth that we are able to offer, we recently extended our relationship with a top 10 biopharmaceutical company to serve as a primary strategic partner for safety assessment services. The incremental work will transition to us over the next 12 to 18 months and meaningfully expand our relationship with this client. With regards to overall demand trends, we are pleased that the improving biopharmaceutical demand environment has remained consistent in recent months and continues to show positive momentum. We are monitoring developments related to inflation, oil prices, interest rates, and the general macroeconomic environment, as well as biotech funding trends for any signs of disruption, but to date, We continue to expect the demand environment to trend favorably. This view is further supported by our internal demand KPIs, which I will discuss in more detail shortly. Our revenue from both global biopharmaceutical and small and mid-sized biotechnology clients increased on an organic basis in the third quarter. There are several factors contributing to these positive trends. First, many of our large biopharmaceutical clients have progressed through their restructuring activities and are in reinvesting in their R&D pipelines, including their preclinical or IND enabling programs, which is a positive indicator for future demand. In addition, as has been well chronicled, the biotech funding environment has improved meaningfully Since the middle of last year, with trailing 12-month funding remaining just below $100 billion despite a modest slowdown in the third quarter. We are not seeing any signs of slowdown in our client interest, supported by another strong increase in DSA proposal activity in the third quarter. This is an indicator that supports our belief that favorable demand trends will continue. And finally, the DSA bookings improvement over the past four quarters, during which time our net book to bill has averaged approximately 1.1 times, has begun to work through the backlog and we're beginning to see the benefits as demonstrated by the improvement in the third quarter revenue growth to the mid-single digits organically for the DSA segment and total companies. I will now provide some highlights from our financial performance before Glenn provides additional detail. First, we are pleased that our third quarter results exceeded our prior outlook for revenue and non-GAAP earnings per share. Third quarter revenue increased 4.7% to the highest level since the second quarter of 2023, with a solid performance in both the DSA and manufacturing segments. The operating margin increased 330 basis points year over year and 250 basis points sequentially to 23% due to operating leverage from higher study volume and lower non-human primate sourcing costs in the DSA segment and the full quarter impact of the divestitures particularly in the manufacturing segment. Non-GAAP earnings per share of $3.09 increased 27% year-over-year and also exceeded our prior outlook due to the strong top line performance and a lower tax rate. Based on our strong third quarter financial performance, we are raising our full year revenue guidance by 100 basis points to organic growth above 1.5%, and non-GAAP earnings per share by 15 cents at midpoint to $11.35 to $11.55. As we discussed at our investor day, we are pleased to see earnings power return as our growth rate accelerates and we generate meaningful operating margin expansions. The organic revenue growth rate in each of our business segments also improved from second quarter levels. DSA revenue growth improved to 5.9% organically in the third quarter, primarily driven by robust demand for safety assessment studies utilizing non-human primates as well as growth for bioanalysis services. As we discussed at our investor day, We believe that we have competitive advantages in the areas of non-human primate supply and preclinical bioanalysis services. They are expected to be important growth drivers and differentiators for Charts River in the future, particularly as demand for biologics and other complex therapies continues to intensify. Regarding the DSA pricing environment, We are beginning to modestly reduce the level of discounting in recent proposals. Our goal over time will be to cover annual cost inflation through price increases and receive the value of services that we provide to our clients. While we are early in this process and are not yet seeing it benefit DSA revenue, we are winning proposals and maintained our capture rate during the third quarter. Assuming the positive trends hold, we do not expect to see any benefit fit from pricing until at least the second half of next year, due to the normal lag as newly booked studies work through the backlog. As I've already mentioned, from a demand perspective, we were pleased to see continued strength in the DSA demand KPIs in the third quarter. Net bookings increased 32% year-over-year to $652 million after the anniversary of the softer bookings that occurred through the third quarter of last year. This resulted in a net book-to-bill of 1.09 times, as well as both year-over-year and sequential increases in the DSA backlog to $2.03 billion. This continues to firmly support our long-term financial targets, including 5-7% DSA organic revenue growth. As I mentioned, proposals showed a strong increase again, marking the fifth consecutive quarter of year-over-year improvement. These trends collectively support our expectations for continued mid-single-digit DSA organic growth in the fourth quarter of this year. Both global biopharmaceutical and small and mid-sized biotechnology clients continue to be key contributors to the demand improvement. Manufacturing revenue rebounded to 7.4% organic growth, with similar growth rates in both the microbial solutions and biologics testing solutions businesses. We were pleased to see the growth rate return to levels that are consistent with our long-term targets for this segment. Our manufacturing quality control testing portfolio leverages many of the strengths of our DSA offering, including enabling clients to drive greater speed and efficiency and also creates additional growth opportunity by deepening our client relationships across the drug development lifecycle. Now that we have divested the CDMO business, and Anniversary, the client-specific issue that has been a headwind for the biologics testing business since mid-2025, we are more clearly seeing the revenue growth and marginal potential for the manufacturing segment. Our matched revenue declined 0.6% organically. The trends have remained consistent all year with strong growth in China, offset by softer demand in North America. Revenue from academic and government accounts was relatively stable globally for the entire RMS segment in the third quarter, as higher revenue in the insourcing solutions business related to government contract awards was offset by lower small model volumes in North America, reflecting continued pressure from uncertainty in government funding. This is one of the reasons that the RMS growth rate has not yet begun to reaccelerate as it has in the DSA and manufacturing segments because global academic and government clients represent a larger portion of RMS revenue at nearly 40%. AI has gotten a lot of attention in recent weeks, so in closing, I want to reaffirm our views on the potential benefits of AI. First, As I noted at our investor day, we believe AI will be a tailwind to our business in the coming years and increase the number of programs that progress through the regulated drug development process, including safety assessment. However, gauging the potential impact of AI on the R&D process will take time because the measure of success will be when more drugs discovered using AI progress through the IND enabling process and into the clinic. But as I said, we are well positioned to take part in this process as demonstrated by our recent collaboration with Eli Lilly's ToonLab initiative and the scientific breadth and depth of our portfolio. Beyond the potential benefits of AI, we are encouraged by the continuous strengths of the underlying biopharmaceutical demand environment. While there are still pockets that have not yet begun to improve, from DSA pricing and startup biotech activity to academic and government client demand, we are pleased with the progress that we have made and the growth prospects ahead. We also see significant opportunities to further strengthen Shantriva's competitive position. With our financial strengths, focused strategy, and deep expertise in regulated testing across the drug development continuum, we are well positioned to meet growing client demand for scientific innovation, speed, and efficiency. Through Pathway to Purpose, We are building a more agile, client-centric organization that will deepen client relationships, expand engagement across our portfolio, and increase our share of R&D spend as demand trends continue to improve. Now, I will turn the call over to Glenn Coleman to provide more details on our third quarter financial performance, as well as to update our 2026 guidance.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-